Glioblastoma multiforme (GBM) is the most common and prognostically unfavorable form of brain tumor. The aggressive and highly invasive phenotype of these tumors makes them among the most anatomically damaging human cancers with a median survival of less than one year.
INTRODUCTION
The WNT signaling pathways, the best studied of which is the canonical (β-CATENIN dependent) branch, are amongst the most evolutionarily conserved and universally important signaling cascades in metazoans, with key roles in cellular proliferation, differentiation, development and function (1, 2) . Dysfunctional WNT signaling has been associated with a variety of human pathologies (3) affecting different cell types and tissues including several types of cancer, bone diseases, and diseases of the central nervous system. An increasing number of studies suggest that aberrant WNT signaling can be initiated by several mechanisms affecting key elements of the pathway (4-11). For instance, mutations (inactivating mutations on APC or AXIN1 tumor suppressor genes or activating mutations on the β-CATENIN oncogene), autocrine activation (increased expression of pathway components including WNT ligands, FRIZZLED (FZD) receptors and DISHEVELLED (DVL) family members) and epigenetic phenomena (e.g. promoter hypermethylation) in negative modulators of the WNT pathway which act homeostatically (e.g.
SFRPs, DKKs and NKDs genes)
. Although studied in multiple diseases, the role and importance of the WNT signaling pathway has not been extensively described in GBM. Recent literature data supports the role of WNT/β-CATENIN signaling in glioma initiation, proliferation and invasion (12) (13) (14) (15) (16) (17) (18) . The protooncogene PLAG2, amplified in GBM, imparts stem-cell properties to glioma cells by regulating WNT signaling (12) . The interaction between the transcription factor FORKHEAD BOX M1 (FOXM1) and β-CATENIN, is a mechanism for controlling canonical WNT signaling and is required for glioma formation (13) . RNAi mediated depletion of the scaffold protein DVL affects proliferation and promotes differentiation of GBM cells in vitro and in vivo (16) . To explore further the relevance of the WNT pathway in GBM and to provide evidence that small molecule inhibition of WNT signaling has therapeutic potential in this CNS tumor, we demonstrate that both genetic and pharmacological WNT inhibition results in modulation of pathway activity at both the biochemical and functional level, and in decreased proliferative capacity both in vitro and in vivo.
SEN461 inhibits canonical Wnt signaling and glioblastoma growth

Primary screening
A structurally diverse, low molecular weight library of 16,000 compounds was screened in stable transfected DBTRG cells containing TCF-Luciferase. For single concentration testing, 6500 cells/well, plated in 96 well-plates were incubated with compounds at 10μM (0.5% DMSO (v/v)) 36 hours after plating. Each compound was tested in duplicate on two different copy cell plates.
Luciferase signal was detected using Luclite Luminescence Reporter Gene Assay System 10000 (Perkin Elmer). Data were expressed as % of negative control (DMSO) and the activity threshold was set to 50% reduction. For IC 50 determination, stable transfected DBTRG cells (plated at the same density used for the single concentration testing) containing TCF-Luciferase and TA-Renilla were incubated with 8-points dilutions (from 60μM to 0.185μM) compound 36 hours after plating. Each compound was tested in triplicate in a single plate. Luciferase detection was done with Dual-Luciferase Reporter Assay System (Promega). For IC 50 calculation, the data were expressed as % of negative control (DMSO) for Firefly and Renilla luciferase independently. Values were calculated using XLFit version 4.2, with a four parameters sigmoid model (XLFit model 205). A luciferase biochemical assay enabled the identification of compounds acting directly on the enzyme rather than true inhibitors. Quantilum recombinant Luciferase (Promega) was employed to test compounds at single concentration (10μM). Data were expressed as % of negative control (DMSO).
Auto-PARsylation reactions
To assess the effect of SEN461 and XAV939 on auto-PARsylation of TANKYRASES, reactions were carried out in 40µl volumes in the presence of the compounds (concentration varying from 0.006 to 100µM, 2.5% DMSO), 20nM GST-TNKS1/2 and 250µM NAD + (Sigma). Reactions were incubated at room temperature for 2 hours and then quenched by adding 10µl of 20% formic Then, 100µl of acetonitrile was added and the samples were centrifuged for 30 min at 3,500 rpm, 4ºC. The supernatant was transferred to a new plate and subjected to the LC/MS analysis, to detect the formation of nicotinamide (a by-product of the PARsylation reaction).
AXIN ubiquitination assay
For the ubiquitination assay DBTRG cells were pre-treated with 10µM SEN461 for 4 hours and subsequently treated with 25µM of the proteasome inhibitor MG-132 (Sigma) in combination with 10μM of SEN461 overnight. Proteins were extracted with Ripa buffer (50mM Tris-HCl ph 7.4, 150mM NaCl, 1% NP40, 0.5% Na-deoxycholate, 0.1% SDS, 1mM EDTA) supplemented with 5mM NEM, to block the activities of deubiquitinase. To immunoprecipitate AXIN2, 1mg of total lysate was incubated 2 hours at 4°C with 3μg of specific antibody and subsequently the immunocomplexes were incubated with Dynabeads Protein-A-conjugated magnetic beads (Dynal) at 4°C overnight. Samples were analyzed by western blotting with anti-multi UBIQUITIN (MBL) antibody.
Immunoblotting and antibodies
Total cells lysates were prepared in RIPA buffer (50mM Tris-HCl ph 7.4, 150mM NaCl, 0.1% SDS, 1% NP-40, 1mM EDTA, 0.5% Na-deoxycholate) containing fresh protease (Sigma) and phosphatase (Upstate) inhibitors cocktail. Cytosolic lysates were prepared using a cell fractionation Kit (Thermo Scientific). Commercial antibodies used in this study include anti-AXIN1, anti-AXIN2, anti-β-CATENIN, anti-P-β−CATENIN Ser33/Ser37/Thr41 and anti-HA from Cell Signaling Technologies, anti-TANKYRASES (Abcam), anti-TUBULIN (Calbiochem), anti-GAPDH (Sigma) and anti-multi UBIQUITIN (MBL). 
qRT-PCR
RNA was extracted from cultured cells using TRIzol reagent (Gibco) followed by isopropanolalcohol precipitation (RNeasy Plus Mini Kit Qiagen) before quantification. Transcript levels were assessed using the Bio-Rad iQ5 (Kit iQ™ SYBR Green Supermix) machine, according to the manufacturer's instructions, and each experiment was repeated three times using independent RNAs samples. Gene expression analysis was performed using the human housekeeping genes, GAPDH and RPL13a. Primers for the hAXIN2 were the following: forward: 5'-CAAGGGCCAGGTCACCAA-3'; reverse: 5'-CCCCCAACCCATCTTCGT-3'.
Transfections, infections and reporter assays
Plasmids and siRNA transfections were carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Inducible lentiviral expression of dominant negative 
FACS analysis
Cell cycle distribution after silencing (siRNA) of β-CATENIN was determined by measuring the amount of cellular DNA using propidium iodide staining. For G 0 /G 1 synchronization, confluent cells were maintained for 24h in complete medium followed by 24h in serum free medium. Cells were then collected by centrifugation and fixed with 50% ethanol overnight. Following fixation, cells were washed with PBS, treated with 100μg/ml RNAse for 15min, and then incubated with 50µg/ml propidium iodide for additional 15min. DNA content was determined using a flow 
Soft agar assay
In the soft agar assay, a suspension of 2.5 x 10 3 cells per well, containing 0.36% (wt/vol) agar, was mixed with various concentrations of compounds, SiRNA or inducible lentiviral vectors prior to setting. The cell layer was overlaid onto a layer of culture medium containing 0.6% (wt/vol) agar in 24-well plates. Subsequently, the plates were kept in culture (37°C and 5% CO 2 ) for 14 or 21 days depending on the cell line. At the end of the incubation, colonies were stained overnight with 5mg/ml of MTT (Sigma) and counted using Oxford Optronix GelCount® instrument.
Xenopus experiments and in vivo tumor growth assay
Xenopus injections were performed as previously described (19). For the glioma xenograft model, 5 x 10 6 DBTRG cells were injected subcutaneously into the right flank of athymic female nude mice (CD-1 nu/nu, Charles Rivers, Calco, Italy). All mice were maintained in a conventional-specific pathogen-free facility (according to the NIH guidelines). Twice a week tumor growth and body weight were evaluated and recorded. Dimensions of the tumors were measured by a digital caliper, and tumor masses were calculated using the following formula:
length (mm) x width 2 (mm) x d/2, assuming density d= 1 mg/mm 3 for tumor tissue. When measurable tumors were established in the majority of mice, animals were randomly assigned into treatment groups (10 mice/group). Animals received the compound by oral gavage at three dose levels and at the dose volume of 10 mL/kg. SEN461 was administered at the following doses and schedules: 30 mg/kg twice daily for 14 consecutive days, 100 mg/kg once daily for 14 consecutive days, 500 mg/kg once weekly for two consecutive weeks. Mice were sacrificed when the tumors reached a volume around 10% of total body weight. 
Statistical analysis
Statistical analysis for soft agar, reporter and qPCR assays was performed with one way Anova test followed by Tukey's test for multiple comparisons. Auto-PARsylation data were analyzed by non-linear regression. Significant difference of embryos developing second axis was tested with
Fischer's exact test, and a t-test was performed on proportions to assess good reproducibility of results across the independent experiments. For the glioma xenograft model, a mixed-effects ANOVA model was performed at the end of the study on body weight and tumor mass data considering "treatment" and "time" as main effects. Statistical analysis was performed using GraphPad Prism and Matlab statistical software.
Compounds
IWR2 and XAV939 molecules were purchased from Asinex and Maybridge respectively. 
RESULTS
Effect of WNT pathway modulation and pathway screening approach to identify small molecule WNT inhibitors in glioma cells
To investigate the consequences of WNT signaling inhibition in glioblastoma, we used the DBTRG-05MG (DBTRG) cell line (20) . The cell line, originally derived from a human recurrent GBM, harbours mutations in PTEN, CDKN2A, and BRAF but has a wild-type TP53 gene constitutive promoter-driven Renilla Luciferase (TA-Renilla) reporter plasmid (alone and in combination) were stably transfected in DBTRG cells and constituted our primary screening assay. As an additional validation step for this readout, we employed the dominant-negative TCF4 (dnTCF4), which cannot bind to β-CATENIN (23, 24) . As result, the output of the Luciferase-based reporter system was strongly inhibited (Supplemental Figure S1D 
SEN461 increases AXIN and decreases β-CATENIN levels in DBTRG cells
In order to link inhibition of WNT signaling and anchorage independent growth in glioblastoma cells we started to analyze the effect of SEN461 treatment on key components of the canonical WNT pathway at the protein level. The effect of SEN461 on AXIN steady-state protein levels was compared to that of XAV939 and IWR2 molecules ( Figure 2) ; two previously published AXIN stabilizers (25, 26) . DBTRG cells treated overnight with two different concentrations (3μM and 10μM) of SEN461 showed an increase of phosphorylated β-CATENIN (a prerequisite for proteasome-mediated degradation of β-CATENIN) in the cytoplasmic fraction, which correlated with a concomitant decrease in the total amount of β-CATENIN, and a simultaneous accumulation of AXIN1 and AXIN2 compared to vehicle (DMSO) treated cells ( Figure 3A) . By contrast, the inactive structural analogue SEN973 didn't produce any such effects (data not shown). As presented in figure 3B , all three small molecules demonstrated comparable effects on the accumulation of both AXIN1 and AXIN2 in DBTRG cells. The increase in AXIN protein levels after compound treatment could be explained by protein stabilization as reported for these recently identified inhibitors of the TANKYRASE (25-27), which acts through AXIN destabilization. It can be hypothesized that SEN461 treatment protected AXIN from proteosomal degradation, because co-treatment of SEN461 and the reversible proteasome inhibitor MG-132 almost completely blocked the ubiquitination of AXIN2 ( Figure 3C ). TANKYRASES, TNKS1 and TNKS2, are enzymes of the PARP family mediating the PARsylation of substrate proteins, a fundamental step in ubiquitin-mediated protein degradation. To test whether the negative modulation of WNT activity induced by SEN461 was the consequence of the inhibition of the PARP catalytic activity of TNKS, we performed biochemical assays for TNKS1 and TNKS2. As shown in the Supplemental Figure S2A , SEN461 showed much weaker activity than XAV939
(from three hundred to almost two thousand folds) in auto-PARsylation of TNKS1 and TNKS2 (IC 50 of 18μM and 2.9μM respectively). Moreover, we also tested whether SEN461 was able to (26) . There was no sign of TNKS stabilization after SEN461 treatment in DBTRG cells (regardless the accumulation of AXIN1), while both IWR2 and XAV939 induced significant TNKS stabilization ( Figure 3D ), as previously reported (26) . A weak TNKS stabilization was observable only following very high (100μM) exposure to SEN461 (Supplemental Figure S2B) . These results suggest that AXIN stabilization induced by SEN461 is accompanied by minimal TNKS stabilization, implying that AXIN stabilization by SEN461 occurs via a mechanism distinct from that by known TNKS inhibitors. The identification of SEN461 as a structurally novel small molecule inhibitor of the WNT pathway acting at the level of AXIN stabilization further supports the modulation of AXIN levels as a pharmacological approach in WNT inhibition. The comparable activity of SEN461, IWR2 and XAV939 in inhibition of TCF-luciferase activity and GBM cell growth in vitro (Supplemental Figure S3) suggests the relevance of such approach for the development of GBM therapeutics.
In vitro and in vivo characterization of WNT signaling inhibition by SEN461
To further characterize the effects of SEN461 on canonical WNT signaling in a different, non GBM cellular background, we investigated the compound in a non-tumorigenic, immortalized cell line widely employed for WNT studies, namely HEK293 cells, where individual WNT ligands can be efficiently expressed and downstream responses studied (28, 29) . In order to study the effects of SEN461 on pathway stimulation by selected WNTs, we transiently co-transfected the Luciferase and Renilla-based reporter plasmids (already employed in the screening campaign) in HEK293 cells transiently overexpressing the canonical WNT pathway ligands WNT1 ( Figure 4A) or WNT3A ( Figure 4B ) alone or in combination with the co-receptor LRP6 (Supplemental Figure   S4 ). WNT1 and WNT3A were chosen because they represent the members of the WNT family with the strongest association with stimulation of the canonical pathway, and because of their (25)). Consistent with the reporter data, the mRNA levels for the WNT/β-CATENIN target gene AXIN2, induced by Wnt3a CM stimulation, was inhibited by SEN461 treatment ( Figure 4D ). The Xenopus axis duplication assay represents a valuable and sensitive way to test the in vivo efficacy and specificity of WNT signaling modulators (34) . Injecton of 10pg of XWnt8 mRNA into the ventral regions of a four-cell stage Xenopus embryo produced ectopic axis formation in almost 80% of the injected embryos ( Figure 5A ). In contrast, co-injection of XWnt8 mRNA with 1 pmol SEN461, produced a 56% reduction of axis duplication compared to DMSO treated embryos ( Figure 5A ). These results support the specific and selective WNT canonical inhibitory activity in both cellular based assays and in vivo.
In-vitro antitumor activity of SEN461 in glioblastoma cell lines
To explore the pharmacological effects of WNT signaling inhibition on glioblastoma cell viability, and to extend the observations obtained in DBTRG cells, we examined the consequences of SEN461 treatment in a set of 9 additional glioma cell lines, either commercially available or primary tumour, patient-derived. As shown in Figure 6A provide additional evidence that WNT signaling activity was indeed responsible for growth inhibition, we transduced T98G (sensitive to genetic WNT inhibition as showed in Figure 6B ) glioblastoma cell line with a doxycyclin (Doxy) inducible dominant negative TCF4 (dnTCF4) lentivirus. As a consequence, we observed a strong decrease in anchorage-independent growth ability (Supplemental Figures S5A) . We next examined the effect of SEN461 treatment on β-CATENIN and AXIN protein levels in T98G cells (Figure 6C) , where we observed a pattern resembling the one already obtained in DBTRG cells: increased phosphorylation of β-CATENIN and stabilized AXIN1 levels, with a concomitant decrease in the cytoplasmic fraction of total β-CATENIN. We then asked whether over-expression of AXIN1 would affect the phenotypic behaviour of the GBM cell lines examined. Indeed this was the case; AXIN1 over-expression showed a profound effect on T98G (Supplemental Figure S5B) as well as on DBTRG (Supplemental Figure S1E) anchorage-independent growth ability, phenocopying the pharmacological effects of SEN461 at a morphological and molecular level.
SEN461 affects tumor growth of DBTRG xenograft model
In order to investigate the relevance of SEN461 antiproliferative capacity in an in vivo setting, a subcutaneous xenograft model was used, to confirm the in vitro observation that WNT/β- 
until Day 79 (more than a month beyond treatment and 51 days after the start of treatment). All schedules were well tolerated with no observable gross toxicities and minimal difference in body weights (Supplemental Figure S6 ) between control and SEN461 treated animals. Analysis on tumor mass showed a very significant effect on treatment (p<< 0.01), and additional pair wise comparison between treatment groups showed all treatments to be significantly different from vehicle. Significant treatment x day effect (p << 0.01) was observed due to a treatment-specific increase of tumor mass over time: vehicle group tumor mass significantly increased starting from day 58 with respect to day 28; on the contrary, tumor mass re-growth on SEN461 treatment is observed only after day 69. At the end of the study, all SEN461 treatments were found to be significantly different from vehicle. The antitumor activity observed for SEN461 at 30 mg/Kg BID shows the highest efficacy level (54% tumor growth inhibition with respect to control group) at the final endpoint (37 days after the end of the treatment). 
DISCUSSION
Despite the efforts to characterize at the molecular level targets and pathways that drive glioma tumorigenesis, the prognosis for patients with such kind of brain tumors remains poor (35) . The complexity of the tumor is increased by its extreme heterogeneity, supported by a vast array of genetic changes and signaling pathways cross-talk (36, 37) , which supply and sustain its high proliferation rate and its ability to infiltrate the surrounding normal parenchyma, representing the major driving force behind tumor recurrence. It has recently been reported that aberrant WNT signaling represents a critical mechanism for the genesis, proliferation and invasion of glioma (12) (13) (14) , suggesting that inhibition of WNT signaling provides an important approach to cancer therapies. Our data support and reinforce the involvement of the WNT signaling pathway in glioblastoma, using either commercially available cell lines or primary patient-derived tumors.
Here we show for the first time that WNT pharmacological modulation in glioblastoma, mediated by a small molecule, can affect therapeutically relevant phenotypes. We demonstrate that the Treatment groups (10 mice per group) were 30 mg/kg twice a day from day 28 to 41, 100 mg/kg/day daily from day 28 to 41 and 500 mg/kg/day once weekly on day 28 and 34. Tumor volume was followed over time until day 79 (37 days after the end of the treatment). 
